HARRISBURG, PA — Three generic drug manufacturers have agreed to antitrust settlements that include $1.05 million in payments to states and restrictions on future business practices, as Pennsylvania and 44 other states and territories pursue allegations of widespread prescription drug price manipulation ahead of a February 2027 trial.
Pennsylvania Attorney General Dave Sunday joined the multistate coalition seeking court approval of agreements with Ascend Laboratories, Citron Pharma and Mayne Pharma. The companies were accused of participating in schemes to inflate generic drug prices, suppress competition and restrict consumer choices.
Under the proposed settlements, Ascend will pay $400,000 and Mayne will pay $650,000 to participating states. Citron’s agreement includes compliance obligations but no monetary payment was specified in the announcement.
All three manufacturers agreed to internal reforms intended to prevent anticompetitive conduct and strengthen compliance with antitrust laws.
The agreements expand a series of settlements stemming from investigations into pricing practices across the generic pharmaceutical industry. Previous settlements with Sandoz, Glenmark, Lannett, Bausch, Apotex, Heritage Pharmaceuticals and Heritage’s parent company, Emcure, totaled $496.5 million.
Including the newly proposed payments, the combined monetary value of the settlements would reach $497.55 million, subject to court approval of the latest agreements.
The litigation centers on allegations that pharmaceutical manufacturers coordinated pricing and other competitive practices in ways that increased prescription drug costs for consumers.
“By limiting market competition while inflating prices, Pennsylvanians had no recourse but to pay unfair prices manipulated by these manufacturers,” Sunday stated.
The cases are supported by an extensive investigation involving cooperating witnesses, more than 20 million documents and millions of telephone records.
Investigators also assembled contact information and call records associated with more than 600 sales and pricing personnel across the generic pharmaceutical industry, according to the Attorney General’s Office.
The evidence forms part of a broader legal effort to establish whether manufacturers coordinated their conduct rather than competing independently on prescription drug pricing.
The latest agreements come as the coalition prepares for its first trial in Hartford, Connecticut, scheduled for February 2027.
The proposed settlements would resolve claims against the three participating manufacturers while leaving the broader litigation to proceed.
Consumers who purchased generic prescription medications between May 2009 and December 2019 may qualify for compensation under the multistate settlement process.
Eligibility information and claim instructions are available at www.AGGenericDrugs.com. Consumers can also call 1-866-290-0182 or email info@AGGenericDrugs.com.
The coalition includes Pennsylvania, Delaware, New Jersey, New York and the District of Columbia, along with 40 other states and territories.
The settlements reflect an ongoing effort by state attorneys general to address alleged anticompetitive practices in the generic drug market, where competition among manufacturers is intended to help keep prescription medication costs lower.
Court approval remains necessary before the three newest agreements become final.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.